Today: 20 May 2026
Browse Category

SGX:SO7 8 December 2025 - 22 December 2025

Yangzijiang Shipbuilding (SGX: BS6) Stock: Latest Price, News, Analyst Forecasts and 2026 Outlook (Dec 22, 2025)

Yangzijiang Shipbuilding (SGX: BS6) Stock: Latest Price, News, Analyst Forecasts and 2026 Outlook (Dec 22, 2025)

Yangzijiang Shipbuilding shares rose 2.37% to S$3.45 on Dec 22, rebounding after a sharp drop earlier in the week. The company’s order book reached about US$22.83 billion as of September 30, with 71% in “green vessels.” Year-to-date, 46 ships have been delivered, 82% of its FY2025 target. Shares now sit near a 52-week high, up 92% from the year’s low.
22 December 2025
··
Yangzijiang Shipbuilding (Holdings) Ltd (SGX: BS6) Stock: Latest News, Order Book Update, and Analyst Forecasts as of 16 Dec 2025

Yangzijiang Shipbuilding (Holdings) Ltd (SGX: BS6) Stock: Latest News, Order Book Update, and Analyst Forecasts as of 16 Dec 2025

Yangzijiang Shipbuilding traded at S$3.49–S$3.50 on 16 Dec 2025, near record highs after a strong 2024–2025. The company reported US$2.2 billion in new orders year-to-date, down from US$11.6 billion a year earlier, but maintained a large US$22.8 billion order book. About 71% of its backlog is for “green vessels.” The group operates mainly in China and is listed in both SGD and RMB on SGX.
16 December 2025
··
Yangzijiang Shipbuilding (SGX: BS6) Stock on 8 December 2025: Record Profits, Green Order Book and Big Analyst Upgrades

Yangzijiang Shipbuilding (SGX: BS6) Stock on 8 December 2025: Record Profits, Green Order Book and Big Analyst Upgrades

Yangzijiang Shipbuilding traded around S$3.37 on 8 December 2025, near the top of its 52-week range after a volatile year. The stock is up roughly 20% over 12 months, with a market cap near S$13.5 billion. Valuations show a trailing P/E of about 9–10x and a dividend yield near 3.5%. The company weathered a sharp drop in early 2025 after US port-fee threats.
8 December 2025
··

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Go toTop